Total Payments
$2.1M
2024 Payments
$360,597
Companies
7
Transactions
516
Payment Breakdown by Category
Consulting$1.7M (78.4%)
Other$317,485 (14.8%)
Travel$116,364 (5.4%)
Research$18,427 (0.9%)
Food & Beverage$10,401 (0.5%)
Education$10.02 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $1.7M | 82 | 78.4% |
| Honoraria | $177,215 | 69 | 8.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $140,270 | 52 | 6.6% |
| Travel and Lodging | $116,364 | 161 | 5.4% |
| Unspecified | $18,427 | 31 | 0.9% |
| Food and Beverage | $10,401 | 120 | 0.5% |
| Education | $10.02 | 1 | 0.0% |
Payments by Type
General
$2.1M
485 transactions
Research
$18,427
31 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Horizon Therapeutics plc | $1.8M | 352 | $0 (2023) |
| Amgen Inc. | $346,665 | 110 | $0 (2024) |
| F. Hoffmann-La Roche AG | $16,501 | 26 | $0 (2024) |
| ARGENX US, INC. | $13,177 | 13 | $0 (2024) |
| H. Lundbeck A S | $7,195 | 3 | $0 (2023) |
| Alexion Pharmaceuticals, Inc. | $4,427 | 11 | $0 (2018) |
| Horizon Pharma plc | $1,103 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $360,597 | 123 | Amgen Inc. ($346,665) |
| 2023 | $797,563 | 93 | Horizon Therapeutics plc ($791,695) |
| 2022 | $441,722 | 119 | Horizon Therapeutics plc ($436,567) |
| 2021 | $290,304 | 76 | Horizon Therapeutics plc ($278,385) |
| 2020 | $145,891 | 41 | Horizon Therapeutics plc ($145,891) |
| 2019 | $99,177 | 52 | Horizon Therapeutics plc ($99,177) |
| 2018 | $4,427 | 11 | Alexion Pharmaceuticals, Inc. ($4,427) |
| 2017 | $1,103 | 1 | Horizon Pharma plc ($1,103) |
All Payment Transactions
516 individual payment records from CMS Open Payments — Page 1 of 21
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | Enspryng (Biological) | — | In-kind items and services | $1,505.36 | Research |
| Study: Assessment of Disability and Disease Burden in Neuromyelitis Optica Spectrum Disorder: Analysis of the CIRCLES Cohort • Category: Immunology | ||||||
| 12/23/2024 | Amgen Inc. | TEPEZZA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,100.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/23/2024 | Amgen Inc. | TEPEZZA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,400.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/23/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | Cash or cash equivalent | $28.52 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/20/2024 | Amgen Inc. | TEPEZZA (Biological) | Travel and Lodging | In-kind items and services | $903.89 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/19/2024 | Amgen Inc. | TEPEZZA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,100.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/19/2024 | Amgen Inc. | TEPEZZA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,700.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/19/2024 | Amgen Inc. | TEPEZZA (Biological) | Travel and Lodging | In-kind items and services | $163.02 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/18/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $123.50 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/18/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $22.77 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/18/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $17.47 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/17/2024 | Amgen Inc. | TEPEZZA (Biological) | Consulting Fee | Cash or cash equivalent | $3,825.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/12/2024 | Amgen Inc. | TEPEZZA (Biological) | Travel and Lodging | In-kind items and services | $1,192.45 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/09/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $149.99 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/08/2024 | Amgen Inc. | TEPEZZA (Biological) | Travel and Lodging | In-kind items and services | $244.03 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/04/2024 | Amgen Inc. | TEPEZZA (Biological) | Travel and Lodging | In-kind items and services | $209.52 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/03/2024 | Amgen Inc. | TEPEZZA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,100.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/03/2024 | Amgen Inc. | TEPEZZA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,400.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/03/2024 | Amgen Inc. | TEPEZZA (Biological) | Travel and Lodging | In-kind items and services | $1,543.75 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/26/2024 | Amgen Inc. | TEPEZZA (Biological) | Consulting Fee | Cash or cash equivalent | $5,156.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/21/2024 | Amgen Inc. | TEPEZZA (Biological) | Consulting Fee | Cash or cash equivalent | $9,100.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/21/2024 | Amgen Inc. | TEPEZZA (Biological) | Consulting Fee | Cash or cash equivalent | $4,875.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/21/2024 | Amgen Inc. | TEPEZZA (Biological) | Consulting Fee | Cash or cash equivalent | $2,063.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/21/2024 | Amgen Inc. | TEPEZZA (Biological) | Travel and Lodging | In-kind items and services | $826.32 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/21/2024 | Amgen Inc. | TEPEZZA (Biological) | Travel and Lodging | In-kind items and services | $784.98 | General |
| Category: Inflammation/Rare Disease | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CLINICAL AND EPIDEMIOLOGICAL CORRELATES OF TREATMENT CHANGE IN PATIENTS WITH NMOSD INSIGHTS FROM THE CIRCLES COHORT | F. Hoffmann-La Roche AG | $2,579 | 1 |
| NOVEL ASSESSMENT OF DISABILITY VS COGNITION AND PAIN IN NEUROMYELITIS OPTICA SPECTRUM DISORDER A CIRCLES COHORT STUDY | F. Hoffmann-La Roche AG | $2,314 | 4 |
| DISEASE PHENOTYPE CORRELATES WITH TREATMENT CHANGE IN NMOSD PATIENTS OF THE CIRCLES COHORT | F. Hoffmann-La Roche AG | $2,004 | 4 |
| CORRELATES OF RITUXIMAB DISCONTINUATION IN PATIENTS WITH NMOSD A CIRCLES COHORT ANALYSIS | F. Hoffmann-La Roche AG | $1,854 | 4 |
| NOVEL DISABILITY ASSESSMENT OF NEUROMYELITIS OPTICA SPECTRUM DISORDER DERIVED FROM THE CIRCLES EXPERIENCE | F. Hoffmann-La Roche AG | $1,815 | 3 |
| Assessment of Disability and Disease Burden in Neuromyelitis Optica Spectrum Disorder: Analysis of the CIRCLES Cohort | F. Hoffmann-La Roche AG | $1,505 | 1 |
| DEMOGRAPHICS AND RELAPSE PROFILE CORRELATES WITH TREATMENT CHANGE IN NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD PATIENTS ANALYSIS OF THE CIRCLES STUDY | F. Hoffmann-La Roche AG | $1,100 | 2 |
| DEMOGRAPHIC AND RELAPSE CORRELATES OF TREATMENT CHANGE IN NMOSD PATIENTS ANALYSIS OF THE CIRCLES STUDY | F. Hoffmann-La Roche AG | $1,083 | 2 |
| RELAPSE PROFILE CORRELATES WITH TREATMENT CHANGE IN NMOSD PATIENTS OF THE CIRCLES COHORT | F. Hoffmann-La Roche AG | $1,061 | 2 |
| Ph2 teprotumumab in patients with active TED | Amgen Inc. | $746.86 | 1 |
| MULTINOMIAL MODELING REVEALS INSIGHTS INTO DISABILITY IN NMOSD A CIRCLES COHORT ANALYSIS | F. Hoffmann-La Roche AG | $598.46 | 2 |
| MULTINOMIAL MODELING REVEALS INSIGHTS INTO DISABILITY IN NMOSD A CIRCLES COHORT ANALYSIS POSTER | F. Hoffmann-La Roche AG | $588.46 | 1 |
| Prevalence of Hearing Dysfunction in Patients With Autoimmune Thyroid Disorders, Thyroid Eye Disease and the General US population: A Claims Database Analysis | Amgen Inc. | $404.00 | 1 |
| Durability of Teprotumumab for the Treatment of Thyroid Eye Disease TED in Clinical Trials | Amgen Inc. | $309.00 | 1 |
| P4 Chronic Inactive TED | Amgen Inc. | $296.67 | 1 |
| Inactive Thyroid Eye Disease Patient Journey | Amgen Inc. | $168.75 | 1 |
About Dr. Terry Smith, M.D
Dr. Terry Smith, M.D is a Internal Medicine healthcare provider based in Ann Arbor, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1306857313.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Terry Smith, M.D has received a total of $2.1M in payments from pharmaceutical and medical device companies, with $360,597 received in 2024. These payments were reported across 516 transactions from 7 companies. The most common payment nature is "Consulting Fee" ($1.7M).
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Diabetes & Metabolism|Endocrinology, Diabetes & Metabolism
- Location Ann Arbor, MI
- Active Since 08/11/2006
- Last Updated 04/10/2009
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1306857313
Products in Payments
- TEPEZZA (Drug) $1.6M
- TEPEZZA (Biological) $341,165
- Enspryng (Biological) $16,501
- VYVGART HYTRULO (Drug) $11,033
- SOLIRIS (Drug) $4,427
- VYVGART (Drug) $2,063
- TEPRO (Drug) $1,103
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Ann Arbor
Dr. Marschall Runge, Md, MD
Internal Medicine — Payments: $2.3M
Internal Medicine $2.3M
Harry Erba, Md, MD
Internal Medicine — Payments: $1.8M
Internal Medicine $1.8M
Dr. Dinesh Khanna, M.d, M.D
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Alexander Yevzlin, Md, MD
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Vallerie Mclaughlin, Md, MD
Internal Medicine — Payments: $1.1M
Internal Medicine $1.1M
Meilan Han, Md, MD
Internal Medicine — Payments: $909,137
Internal Medicine $909,137